Mar 16, 2023 / 11:30AM GMT
Operator
Ladies and gentlemen, good day, and welcome to the conference call of Eris Lifesciences Limited. We have with us today on the call Mr. Amit Bakshi, Chairman and Managing Director; and Mr. V. Krishnakumar, Executive Director and Chief Operating Officer. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. V Krishnakumar, Executive Director and Chief Operating Officer. Thank you, and over to you, sir.
Krishnakumar Vaidyanathan - Eris Lifesciences Limited - Executive Director & COO
Thank you, Nirav. I'm Krishna Kumar, and I welcome you all to this call to discuss our latest acquisition. Before we get into the specifics of our deal, I wish to take a few minutes to recap the (inaudible) of our inorganic strategy. As discussed several times in the past, the key thrust of our inorganic strategy is to (inaudible) our presence in attractive therapy areas.
We leveraged the stride acquisition to enter the CNS therapy. We entered the insulin segment through an equity venture with (inaudible)
Eris Lifesciences Ltd to Announce Acquisition of Nine Dermatology Brands From Dr Reddy's Laboratories Ltd Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot